Basal Cell Nevus Syndrome
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AT
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GenentechVismodegib
Ascend TherapeuticsASN-002
Clinical Trials (2)
Total enrollment: 24 patients across 2 trials
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
Start: Apr 2012Est. completion: Dec 201524 patients
Phase 2Completed
A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
Start: Sep 2015Est. completion: Nov 2017
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space